Horama develops gene therapies for rare inherited ocular and CNS (central nervous system) diseases.
Coave Therapeutics has raised $32.9M in total funding. The most recent round was Series A. The last funding was announced in January 2025.
Coave Therapeutics's investors include Bpifrance, Novo Holdings, Omnes Capital, Kurma Partners, GO CAPITAL.
Coave Therapeutics is headquartered in Paris, France.
Horama develops gene therapies for rare inherited ocular and CNS (central nervous system) diseases.
Coave Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Coave Therapeutics — Funding & Investors." VCBacked, January 9, 2025, https://www.vcbacked.co/company/coave-therapeutics. Accessed September 10, 2026.
VCBacked. (2025). Coave Therapeutics — Funding & Investors. Retrieved September 10, 2026, from https://www.vcbacked.co/company/coave-therapeutics
{{cite web |title=Coave Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/coave-therapeutics |website=VCBacked |access-date=September 10, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated